's Chart of the Day - Quidel
Related Stocks
 QDEL - Quidel Cp

TheBarchart Chart of the Daybelongs toQuidel(QDEL). I found the medical products stock by using Barchart to sort today'sTop Stocks to Ownlist first for the highest Weighted Alpha, Then I used the Flipchart feature to review the charts for consistent price appreciation over the last 6 months. Since the Trend Spotter signaled a buy on 5/9 the stock gained 5.24%.

Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis.


Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on theBarchart.comwebsite when you read this report.

Barchart technical indicators:

  • 96% technical buy signals
  • 125.99+ Weighted Alpha
  • 159.57% gain in the last year
  • Trend Spotter buy signals
  • Above its 20, 50 and 100 day moving averages
  • 10 new highs and up 13.94% in the last month
  • Relative Strength Index 68.96%
  • Technical support level at 63.20
  • Recently traded at 63.48 with a 50 day moving average of 54.66

Fundamental factors:

  • Market Cap $2.40 billion
  • P/E 103.69
  • Revenue expected to grow 81.70% this year and another 4.70% next year
  • Earnings estimated to increase 1586.70% this year, an additional 12.60% next year and continue to compound at an annual rate of 48.00% for the next 5 years
  • Wall Street analysts issued 2 strong buy, 2 buy and 2 hold recommendations on the stock